|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Biosynexus, Inc. Acquired By QVT Fund LP; Irwin Scher Named CEO Of Biosynexus Incorporated
10/19/2005 5:08:54 PM
GAITHERSBURG, Md. & NEW YORK--(BUSINESS WIRE)--June 14, 2005--Biosynexus Incorporated, a biotechnology-pharmaceutical company that is commercializing a portfolio of products for the prevention and treatment of infectious diseases, announced today that Biosynexus became a wholly owned subsidiary of QVT Fund LP, as of May 26th, 2005. Biosynexus also announced that Dr. Irwin Scher has been appointed Chief Executive Officer.
Prior to joining Biosynexus, Dr. Scher served as a consultant to the CEO of Merck KGaA and as Vice President, Global Clinical Research & Development at Merck KGaA. Prior to this, he held the roles of Senior Vice President, Drug Development and Medical Affairs at Astra-Zeneca, and of Vice President Drug Development at Merck & Company Inc. Dr. Scher is a veteran of academic medicine, having spent fourteen years at the National Naval Medical Center, the Naval Medical Research Institute and the Uniformed Services University as the director of Rheumatology.
|
|
|
|
|
|
|
|
|
|
|